Towa Pharmaceutical Co., Ltd. announced earnings results for the second quarter of fiscal year 2016. For the period, the company reported net sales of JPY 39,162 million compared to JPY 33,468 million a year ago. Operating income was JPY 5,522 million compared to JPY 4,183 million a year ago. Ordinary income was JPY 5,613 million compared to JPY 5,550 million a year ago. Profit attributable to owners of parent was JPY 4,014 million compared to JPY 4,068 million a year ago.

The company provided earnings guidance for the full year ending March 2016. For the period, the company expects net sales of JPY 82,000 million, operating income of JPY 11,500 million, ordinary income of JPY 11,500 million and profit attributable to owners of parent of JPY 8,200 million. The company revised capital expenditure guidance of JPY 18,100 million against previous guidance of JPY 13,600 million

For the year ending March 2017, the company revised capital expenditure guidance of JPY 20,700 million against previous guidance of JPY 17,000 million.

For the year ending March 2018, the company revised capital expenditure guidance of JPY 39,000 million against previous guidance of JPY 20,000 million.